
-
British cycling icon Hoy and wife provide solace for each other's ills
-
Money, power, violence in high-stakes Philippine elections
-
Iran, US hold second round of high-stakes nuclear talks in Rome
-
Japanese warships dock at Cambodia's Chinese-renovated naval base
-
US Supreme Court pauses deportation of Venezuelans from Texas
-
Pakistan foreign minister arrives in Kabul as Afghan deportations rise
-
Heat and Grizzlies take final spots in the NBA playoffs
-
Iran, US to hold second round of high-stakes nuclear talks in Rome
-
Humanoid robots stride into the future with world's first half-marathon
-
Migrant's expulsion puts Washington Salvadorans on edge
-
Plan for expanded Muslim community triggers hope, fear in Texas
-
Pakistan foreign minister due in Kabul as deportations rise
-
White House touts Covid-19 'lab leak' theory on revamped site
-
Dodgers star Ohtani skips trip to Texas to await birth of first child
-
SFWJ / Medcana Announces Strategic Expansion Into Australia With Acquisition of Cannabis Import and Distribution Licenses
-
US senator says El Salvador staged 'margarita' photo op
-
Ford 'adjusts' some exports to China due to tariffs
-
Thomas maintains two-shot lead at RBC Heritage
-
US to withdraw some 1,000 troops from Syria
-
Four killed after spring storms wreak havoc in the Alps
-
Spurs' Popovich reportedly home and well after 'medical incident'
-
Trump goes to war with the Fed
-
Celtics chase second straight NBA title in playoff field led by Thunder, Cavs
-
White House site blames China for Covid-19 'lab leak'
-
Norris edges Piastri as McLaren top Jeddah practice
-
Trump warns US could ditch Ukraine talks if no progress
-
Judge denies Sean 'Diddy' Combs push to delay trial
-
80 killed in deadliest US attack on Yemen, Huthis say
-
Lebanon says two killed in Israeli strikes in south
-
Trump says US will soon 'take a pass' if no Ukraine deal
-
F1 success is 'like cooking' - Ferrari head chef Vasseur
-
Cycling mulls slowing bikes to make road racing safer
-
Macron invites foreign researchers to 'choose France'
-
Klopp 'happy' in new job despite Real Madrid rumours: agent
-
Alcaraz into Barcelona semis as defending champion Ruud exits
-
Vance meets Italy's Meloni before Easter at the Vatican
-
Evenepoel returns with victory in Brabantse Pijl
-
Maresca confident he will survive Chelsea slump
-
Mob beats to death man from persecuted Pakistan minority
-
Lebanon says one killed in Israeli strike near Sidon
-
Arsenal's Havertz could return for Champions League final
-
US officials split on Ukraine truce prospects
-
Client brain-dead after Paris cryotherapy session goes wrong
-
Flick demands answers from La Liga for 'joke' schedule
-
'Maddest game' sums up Man Utd career for Maguire
-
Trial opens for students, journalists over Istanbul protests
-
Gaza rescuers say Israeli strikes kill 24 after Hamas rejects truce proposal
-
'Really stuck': Ukraine's EU accession drive stumbles
-
'Not the time to discuss future', says Alonso amid Real Madrid links
-
74 killed in deadliest US attack on Yemen, Huthis say

Lumira Ventures Announces Promotion of Suman Rao to Principal
Lumira Ventures, a leading North American life sciences investment firm dedicated to advancing healthcare innovation and enhancing patient outcomes, is pleased to announce the promotion of Suman Rao, Ph.D., to the role of Principal. This well-deserved promotion acknowledges her significant contributions to the firm's success and her steadfast commitment to fostering innovative healthcare solutions.
Dr. Rao joined Lumira Ventures in 2021 as an Associate and was promoted to Senior Associate in 2024, as she built out her skills and experience in all dimensions of the venture capital value chain. Her deep understanding of industry sectors like oncology and neuroscience coupled with her ability to foster strong relationships with entrepreneurs, co-investors, and industry stakeholders has made her a sought-after team member. Dr. Rao has been deeply involved with the firm's investments in Arclight Therapeutics, Congruence Therapeutics, and Damona Pharmaceuticals (as a board observer). Her contributions extend to being actively engaged in a number of the firm's strategic initiatives, including the Angelini Lumira Biosciences Fund and currently co-leading the Cancer Breakthrough Fund, a first-of-its-kind collaboration in Canada between a philanthropic organization (Terry Fox Foundation) and a VC firm with the goal to bring more capital to the mission of finding cures for cancers.
"We are delighted to elevate Suman to the role of Principal," said Peter van der Velden, Managing General Partner at Lumira Ventures. "Her growth at the firm and ability to take on more responsibility reflects our commitment to growing talent in-house and her dedication to developing the skills, expertise, and relationships that are the foundation of being a great VC."
"I am thrilled to be stepping into the role of Principal and grateful for the trust and support of my partners and colleagues," said Dr. Rao. "Together with an incredibly talented team, I look forward to supporting passionate entrepreneurs tackling some of medicine's biggest challenges today and building transformative companies."
Dr. Rao earned her Ph.D. in Experimental Medicine and her Bachelor's degree in Biochemistry from McGill University. Before joining Lumira Ventures, she completed a prestigious postdoctoral fellowship at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Rao also brings valuable experience from her time as a management consultant at L.E.K Consulting, where she provided strategic advice to biotech and pharma clients, further honing her expertise in the life sciences sector.
About Lumira Ventures
Lumira Ventures is a leading multi-stage life sciences investment firm operating across Toronto, Montréal, Vancouver, and Boston. As Canada's largest and most active dedicated life sciences venture capital investor, Lumira invests in first-in-class innovations in "secondary" geographies, partnering with mission-driven entrepreneurs to develop transformative therapeutics products and medical devices while generating strong financial returns and societal impact.
With a proven track record, Lumira Ventures has consistently delivered both financial success and transformative medical advancements. With portfolio companies having introduced over 50 biomedical innovations, improving the lives of over 1 billion patients worldwide and generating more than $70B in cumulative revenue.
For more information, please contact: [email protected]
www.lumiraventures.com
SOURCE: Lumira Ventures
L.Mason--AMWN